Cowen & Co. Initiates Coverage On Novavax with Outperform Rating, Announces Price Target of $150
Cowen & Co. analyst Georgi Yordanov initiates coverage on Novavax (NASDAQ:NVAX) with a Outperform rating and announces Price Target of $150.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows.
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker’s Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours:
Novavax Scores Approval From Australian Regulator For COVID-19 Vaccine
Novavax Inc (NASDAQ: NVAX) said Wednesday that Australia’s national drugs regulator has granted approval for its COVID-19 vaccine.
This Is What Whales Are Betting On Novavax
A whale with a lot of money to spend has taken a noticeably bullish stance on Novavax.
Looking at options history for Novavax (NASDAQ:NVAX) we detected 34 strange trades.
Why Moderna, Pfizer, BioNTech And Novavax Shares Are Falling Today
Shares of vaccine makers, including Moderna Inc (NASDAQ: MRNA), BioNTech SE - ADR (NASDAQ: BNTX) and Novavax, Inc.
EU Regulator Says No Evidence Seen Yet To Recommend 4th Dose Of COVID-19 Vaccines
-Bloomberg-Bloomberg
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Why Moderna, Novavax And Other Vaccine Stocks Are Extending Losses Today
COVID-19 vaccine stocks are all retreating sharply for a second day running on Friday.